Logo image of BPMC

BLUEPRINT MEDICINES CORP (BPMC) Stock Fundamental Analysis

NASDAQ:BPMC - US09627Y1091 - Common Stock

129.46 USD
+0.18 (+0.14%)
Last: 7/17/2025, 8:06:04 PM
129.5 USD
+0.04 (+0.03%)
After Hours: 7/17/2025, 8:06:04 PM
Fundamental Rating

4

BPMC gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 541 industry peers in the Biotechnology industry. BPMC has a bad profitability rating. Also its financial health evaluation is rather negative. BPMC shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

BPMC had negative earnings in the past year.
In the past year BPMC has reported a negative cash flow from operations.
BPMC had negative earnings in 4 of the past 5 years.
BPMC had negative operating cash flow in 4 of the past 5 years.
BPMC Yearly Net Income VS EBIT VS OCF VS FCFBPMC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M -600M

1.2 Ratios

BPMC has a Return On Assets of -13.03%. This is amongst the best in the industry. BPMC outperforms 82.55% of its industry peers.
BPMC has a Return On Equity of -45.52%. This is in the better half of the industry: BPMC outperforms 67.63% of its industry peers.
Industry RankSector Rank
ROA -13.03%
ROE -45.52%
ROIC N/A
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
BPMC Yearly ROA, ROE, ROICBPMC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

BPMC's Gross Margin of 96.48% is amongst the best of the industry. BPMC outperforms 96.22% of its industry peers.
In the last couple of years the Gross Margin of BPMC has grown nicely.
BPMC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.48%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
BPMC Yearly Profit, Operating, Gross MarginsBPMC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

3

2. Health

2.1 Basic Checks

BPMC does not have a ROIC to compare to the WACC, probably because it is not profitable.
BPMC has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BPMC has more shares outstanding
The debt/assets ratio for BPMC is higher compared to a year ago.
BPMC Yearly Shares OutstandingBPMC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BPMC Yearly Total Debt VS Total AssetsBPMC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

BPMC has an Altman-Z score of 3.51. This indicates that BPMC is financially healthy and has little risk of bankruptcy at the moment.
BPMC's Altman-Z score of 3.51 is fine compared to the rest of the industry. BPMC outperforms 74.10% of its industry peers.
BPMC has a Debt/Equity ratio of 1.01. This is a high value indicating a heavy dependency on external financing.
BPMC has a Debt to Equity ratio of 1.01. This is in the lower half of the industry: BPMC underperforms 76.80% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF N/A
Altman-Z 3.51
ROIC/WACCN/A
WACC10.27%
BPMC Yearly LT Debt VS Equity VS FCFBPMC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

BPMC has a Current Ratio of 2.80. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.80, BPMC is doing worse than 66.73% of the companies in the same industry.
BPMC has a Quick Ratio of 2.75. This indicates that BPMC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.75, BPMC is doing worse than 65.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.8
Quick Ratio 2.75
BPMC Yearly Current Assets VS Current LiabilitesBPMC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.24% over the past year.
The Revenue has grown by 99.14% in the past year. This is a very strong growth!
Measured over the past years, BPMC shows a very strong growth in Revenue. The Revenue has been growing by 50.23% on average per year.
EPS 1Y (TTM)57.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.94%
Revenue 1Y (TTM)99.14%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%55.45%

3.2 Future

Based on estimates for the next years, BPMC will show a very strong growth in Earnings Per Share. The EPS will grow by 28.63% on average per year.
BPMC is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.27% yearly.
EPS Next Y76.13%
EPS Next 2Y50.32%
EPS Next 3Y46.02%
EPS Next 5Y28.63%
Revenue Next Year41.72%
Revenue Next 2Y37.18%
Revenue Next 3Y32.66%
Revenue Next 5Y26.27%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BPMC Yearly Revenue VS EstimatesBPMC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
BPMC Yearly EPS VS EstimatesBPMC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 10 -10 20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BPMC. In the last year negative earnings were reported.
BPMC is valuated quite expensively with a Price/Forward Earnings ratio of 131.18.
Based on the Price/Forward Earnings ratio, BPMC is valued cheaper than 87.77% of the companies in the same industry.
BPMC is valuated expensively when we compare the Price/Forward Earnings ratio to 22.66, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 131.18
BPMC Price Earnings VS Forward Price EarningsBPMC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BPMC Per share dataBPMC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
BPMC's earnings are expected to grow with 46.02% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.32%
EPS Next 3Y46.02%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BPMC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BLUEPRINT MEDICINES CORP

NASDAQ:BPMC (7/17/2025, 8:06:04 PM)

After market: 129.5 +0.04 (+0.03%)

129.46

+0.18 (+0.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners109.31%
Inst Owner Change-12.23%
Ins Owners0.84%
Ins Owner Change-180.68%
Market Cap8.37B
Analysts68
Price Target132.96 (2.7%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-24.05%
Min EPS beat(2)-38.05%
Max EPS beat(2)-10.05%
EPS beat(4)2
Avg EPS beat(4)0.22%
Min EPS beat(4)-38.05%
Max EPS beat(4)39.24%
EPS beat(8)6
Avg EPS beat(8)7.49%
EPS beat(12)9
Avg EPS beat(12)6.42%
EPS beat(16)11
Avg EPS beat(16)-9.61%
Revenue beat(2)0
Avg Revenue beat(2)-3.69%
Min Revenue beat(2)-5.77%
Max Revenue beat(2)-1.61%
Revenue beat(4)1
Avg Revenue beat(4)5.58%
Min Revenue beat(4)-5.77%
Max Revenue beat(4)30.77%
Revenue beat(8)5
Avg Revenue beat(8)10.01%
Revenue beat(12)8
Avg Revenue beat(12)15.3%
Revenue beat(16)11
Avg Revenue beat(16)15.01%
PT rev (1m)0.02%
PT rev (3m)3.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-36.4%
EPS NY rev (1m)0%
EPS NY rev (3m)23.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.27%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 131.18
P/S 14.89
P/FCF N/A
P/OCF N/A
P/B 24.47
P/tB 24.47
EV/EBITDA N/A
EPS(TTM)-3.22
EYN/A
EPS(NY)0.99
Fwd EY0.76%
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS8.69
BVpS5.29
TBVpS5.29
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.03%
ROE -45.52%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.48%
FCFM N/A
ROA(3y)-31.77%
ROA(5y)-25.69%
ROE(3y)-172.98%
ROE(5y)-112.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.19%
GM growth 5YN/A
F-Score3
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 1.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.61%
Cap/Sales 0.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.8
Quick Ratio 2.75
Altman-Z 3.51
F-Score3
WACC10.27%
ROIC/WACCN/A
Cap/Depr(3y)80.73%
Cap/Depr(5y)67.67%
Cap/Sales(3y)3.9%
Cap/Sales(5y)2.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%43.94%
EPS Next Y76.13%
EPS Next 2Y50.32%
EPS Next 3Y46.02%
EPS Next 5Y28.63%
Revenue 1Y (TTM)99.14%
Revenue growth 3Y41.37%
Revenue growth 5Y50.23%
Sales Q2Q%55.45%
Revenue Next Year41.72%
Revenue Next 2Y37.18%
Revenue Next 3Y32.66%
Revenue Next 5Y26.27%
EBIT growth 1Y60.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.02%
EBIT Next 3Y49.05%
EBIT Next 5Y35.74%
FCF growth 1Y69.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.45%
OCF growth 3YN/A
OCF growth 5YN/A